Table 3.
Parameter | Aerobika* device | No PEP/OPEP therapy |
---|---|---|
Total direct medical cost | $7,829 | $8,382 |
Total exacerbations (average #/patient) | 0.77 | 0.83 |
Cost savings | $553/patient | |
Number of exacerbations avoided | 0.06 (ie, six per 100 patients) | |
ICER | Aerobika* device is the dominant strategy |
Abbreviations: ICER, incremental cost-effectiveness ratio; OPEP, oscillating positive expiratory pressure; PEP, positive expiratory pressure.